VRCA
ACHAT TOTAL: 25 000 titres (~125 750,00 $ US)
- Insiders
- Rieger Jayson
- Total bought
- $125,750
- Total sold
- —
- Last activity
- 2026-08-17
- Last synced
-
2026-08-23 00:12:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-26
VRCA presents a mixed signal: a moderate insider buy and an Israel distribution agreement provide genuine near-term catalysts, but the company's weak financial health (persistent cash burn, negative operating margins…
The first sentence of the analysis written for VRCA on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 90.3% | 63.8% | 85.4% | 92.0% | 96.1% | |
| Ebit Margin | -28.5% | -887.7% | -1230.2% | -247.1% | -256.5% | |
| Ebitda Margin | -26.3% | -871.0% | -1213.8% | -239.1% | -252.6% | |
| Operating Profit Margin | -33.6% | -871.3% | -1283.4% | -235.8% | -257.6% | |
| Pretax Profit Margin | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% | |
| Continuous Operations Profit Margin | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% | |
| Net Profit Margin | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% | |
| Bottom Line Profit Margin | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% | |
| Current Ratio | 2.588 | 1.764 | 4.554 | 11.308 | 1.614 | |
| Quick Ratio | 2.452 | 1.679 | 4.494 | 11.308 | 1.614 | |
| Solvency Ratio | -0.764 | -1.177 | -1.070 | -5.070 | -0.728 | |
| Cash Ratio | 1.834 | 1.597 | 4.085 | 9.908 | 0.342 | |
| Price To Earnings Ratio | -4.946 | -0.474 | -4.953 | -3.835 | -7.062 | |
| Price To Earnings Growth Ratio | 0.056 | 0.000 | -0.047 | 0.086 | 0.293 | |
| Forward Price To Earnings Growth Ratio | 0.056 | 0.000 | -0.047 | 0.086 | 0.293 | |
| Price To Earnings Diluted Ratio | -4.946 | -0.474 | -4.953 | -3.835 | -7.062 | |
| Price To Earnings Diluted Growth Ratio | 0.056 | 0.000 | -0.047 | 0.086 | 0.293 | |
| Price To Book Ratio | 3.578 | -3.678 | 16.794 | 2.347 | 7.598 | |
| Price To Sales Ratio | 2.488 | 4.793 | 64.775 | 10.402 | 20.644 | |
| Price To Free Cash Flow Ratio | -5.022 | -0.595 | -8.524 | -4.957 | -8.703 | |
| Price To Operating Cash Flow Ratio | -5.022 | -0.595 | -8.604 | -5.038 | -8.981 | |
| Debt To Assets Ratio | 0.035 | 0.849 | 0.558 | 0.034 | 0.542 | |
| Debt To Equity Ratio | 0.066 | -4.659 | 2.303 | 0.038 | 1.331 | |
| Debt To Capital Ratio | 0.062 | 1.273 | 0.697 | 0.037 | 0.571 | |
| Long Term Debt To Capital Ratio | 0.000 | 1.467 | 0.684 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.905 | -5.490 | 4.129 | 1.117 | 2.457 | |
| Working Capital Turnover Ratio | 1.474 | 0.183 | 0.107 | 0.283 | 0.425 | |
| Operating Cash Flow Ratio | -1.072 | -2.100 | -2.266 | -5.392 | -0.599 | |
| Operating Cash Flow Sales Ratio | -0.495 | -8.053 | -7.529 | -2.065 | -2.299 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.009 | 1.016 | 1.032 | |
| Debt Service Coverage Ratio | -1.209 | -2.948 | -15.698 | -9.943 | -0.659 | |
| Interest Coverage Ratio | -1.542 | -7.004 | -16.597 | -9.805 | -7.196 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -4.709 | 0.000 | 0.000 | -0.662 | |
| Operating Cash Flow Coverage Ratio | -10.807 | -1.326 | -0.848 | -12.221 | -0.635 | |
| Capital Expenditure Coverage Ratio | 0.000 | -2,256.556 | -106.566 | -61.755 | -31.237 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -2,256.556 | -106.566 | -61.755 | -31.237 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.409 | -0.544 | -4.950 | -2.834 | -9.085 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 90.3% | ▲26.5% | ▲4.8% |
| Ebit Margin | -28.5% | ▲859.2% | ▲501.5% |
| Ebitda Margin | -26.3% | ▲844.7% | ▲494.2% |
| Operating Profit Margin | -33.6% | ▲837.7% | ▲502.7% |
| Pretax Profit Margin | -50.3% | ▲961.9% | ▲536.4% |
| Continuous Operations Profit Margin | -50.3% | ▲961.9% | ▲536.4% |
| Net Profit Margin | -50.3% | ▲961.9% | ▲536.4% |
| Bottom Line Profit Margin | -50.3% | ▲961.9% | ▲536.4% |
| Current Ratio | 2.588 | ▲0.824 | ▼-1.778 |
| Quick Ratio | 2.452 | ▲0.773 | ▼-1.857 |
| Solvency Ratio | -0.764 | ▲0.413 | ▲0.998 |
| Cash Ratio | 1.834 | ▲0.237 | ▼-1.719 |
| Price To Earnings Ratio | -4.946 | ▼-4.473 | ▼-0.692 |
| Price To Earnings Growth Ratio | 0.056 | ▲0.056 | ▼-0.022 |
| Forward Price To Earnings Growth Ratio | 0.056 | ▲0.056 | ▼-0.022 |
| Price To Earnings Diluted Ratio | -4.946 | ▼-4.473 | ▼-0.692 |
| Price To Earnings Diluted Growth Ratio | 0.056 | ▲0.056 | ▼-0.022 |
| Price To Book Ratio | 3.578 | ▲7.256 | ▼-1.750 |
| Price To Sales Ratio | 2.488 | ▼-2.305 | ▼-18.132 |
| Price To Free Cash Flow Ratio | -5.022 | ▼-4.427 | ▲0.538 |
| Price To Operating Cash Flow Ratio | -5.022 | ▼-4.427 | ▲0.626 |
| Debt To Assets Ratio | 0.035 | ▼-0.814 | ▼-0.369 |
| Debt To Equity Ratio | 0.066 | ▲4.725 | ▲0.250 |
| Debt To Capital Ratio | 0.062 | ▼-1.211 | ▼-0.466 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-1.467 | ▼-0.430 |
| Financial Leverage Ratio | 1.905 | ▲7.395 | ▲1.081 |
| Working Capital Turnover Ratio | 1.474 | ▲1.291 | ▲0.980 |
| Operating Cash Flow Ratio | -1.072 | ▲1.028 | ▲1.213 |
| Operating Cash Flow Sales Ratio | -0.495 | ▲7.557 | ▲3.593 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.000 | ▼-0.012 |
| Debt Service Coverage Ratio | -1.209 | ▲1.739 | ▲4.882 |
| Interest Coverage Ratio | -1.542 | ▲5.462 | ▲6.887 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲4.709 | ▲1.074 |
| Operating Cash Flow Coverage Ratio | -10.807 | ▼-9.481 | ▼-5.640 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲2256.556 | ▲491.223 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲2256.556 | ▲491.223 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.409 | ▼-5.864 | ▼-1.644 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $88.5M | $36.3M | $331.9M | $93.9M | $247.7M | |
| Enterprise value | $60.0M | $35.9M | $307.9M | $61.2M | $275.4M | |
| EV / Sales | 1.69x | 4.74x | 60.08x | 6.78x | 22.95x | |
| EV / Op. cash flow | -3.40x | -0.59x | -7.98x | -3.28x | -9.98x | |
| EV / Free cash flow | -3.40x | -0.59x | -7.91x | -3.23x | -9.67x | |
| EV / EBITDA | -6.41x | -0.54x | -4.95x | -2.83x | -9.09x | |
| Net debt / EBITDA | 3.05x | 0.01x | 0.39x | 1.52x | -0.91x | |
| Current ratio | 2.59x | 1.76x | 4.55x | 11.31x | 1.61x | |
| Income quality | 0.99x | 0.80x | 0.58x | 0.76x | 0.79x | |
| Graham net-net | $1 | -$3 | $3 | $9 | $8 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 176.3% | 114.0% | 106.3% | 109.7% | 114.0% | |
| Working capital | $26.1M | $22.2M | $60.5M | $35.7M | $28.3M | |
| Invested capital | $28.0M | $24.7M | $64.1M | $41.0M | $33.8M | |
| Return on assets | -37.9% | -141.5% | -82.1% | -54.8% | -43.8% | |
| Operating ROA | -23.6% | -97.1% | -104.1% | -34.1% | -40.1% | |
| Return on tangible assets | -37.9% | -141.5% | -82.1% | -54.8% | -43.8% | |
| Return on equity | -72.3% | 776.7% | -339.0% | -61.2% | -107.6% | |
| Return on invested capital | -38.0% | -170.2% | -100.7% | -51.2% | -40.7% | |
| Return on capital employed | -38.9% | -262.4% | -101.8% | -51.6% | -90.7% | |
| Earnings yield | -20.2% | -211.2% | -20.2% | -26.1% | -14.2% | |
| Free cash flow yield | -19.9% | -168.1% | -11.7% | -20.2% | -11.5% | |
| Capex / Op. cash flow | 0.0% | -0.0% | -0.9% | -1.6% | -3.2% | |
| Capex / Depreciation | 0.0% | 2.1% | 43.3% | 42.1% | 187.1% | |
| Capex / Sales | 0.0% | 0.4% | 7.1% | 3.3% | 7.4% | |
| SG&A / Sales | 99.0% | 777.5% | 923.2% | 192.7% | 224.8% | |
| R&D / Sales | 24.9% | 156.5% | 396.1% | 135.1% | 132.7% | |
| Stock comp / Sales | 9.3% | 94.7% | 280.6% | 55.2% | 50.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 55d | 4d | 315d | 20d | 0d | |
| Days payables outstanding | 220d | 253d | 1206d | 255d | 653d | |
| Operating cycle | 293d | 332d | 815d | 20d | 0d | |
| Cash conversion cycle | 73d | 79d | -391d | -236d | -653d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+144.1%EV / Sales ▼-64.4%EV / EBITDA ▼-1077.2%EV / Op. cash flow ▼-2.815Earnings yield ▲+1.910
Profitability
Return on equity ▼-8.490Return on assets ▲+1.035Return on invested capital ▲+1.322Return on capital employed ▲+2.235Operating ROA ▲+0.736Income quality ▲+0.190Tax burden 0.000
Efficiency
Days sales outstanding ▲+51.656Days payables outstanding ▼-32.784Operating cycle ▼-39.264Cash conversion cycle ▼-6.479Capex / Sales ▼-0.004R&D / Sales ▼-1.316
Balance-sheet strength
Current ratio ▲+0.824Net debt / EBITDA ▲+3.040Working capital ▲+3935000.000Invested capital ▲+3218000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-64.3%EV / Sales ▼-92.7%EV / EBITDA ▲+29.5%EV / Op. cash flow ▲+6.580Earnings yield ▼-0.060
Profitability
Return on equity ▲+0.353Return on assets ▲+0.058Return on invested capital ▲+0.027Return on capital employed ▲+0.518Operating ROA ▲+0.165Income quality ▲+0.199Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-433.658Operating cycle n/aCash conversion cycle ▲+726.209Capex / Sales ▼-0.074R&D / Sales ▼-1.079
Balance-sheet strength
Current ratio ▲+0.974Net debt / EBITDA ▲+3.958Working capital ▼-2171000.000Invested capital ▼-5811000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-07 Verrica Pharmaceuticals Q2 Earnings Call Highlights Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028.
- 2026-08-07 Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
- 2026-07-30 Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m.
- 2026-07-21 Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd.
- 2026-06-22 Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts - WEST CHESTER, Pa.
- 2026-06-22 Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts – Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –
- 2026-05-28 Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference.